BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 296 filers reported holding BLUEBIRD BIO INC in Q1 2019. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $89,000 | +117.1% | 14,000 | +40.0% | 0.00% | – |
| Q2 2022 | $41,000 | -98.4% | 10,000 | -87.6% | 0.00% | -100.0% |
| Q2 2021 | $2,575,000 | +63.7% | 80,537 | +54.4% | 0.01% | +75.0% |
| Q1 2021 | $1,573,000 | -66.3% | 52,167 | -51.6% | 0.00% | -60.0% |
| Q4 2020 | $4,661,000 | -12.6% | 107,700 | +9.0% | 0.01% | -28.6% |
| Q3 2020 | $5,330,000 | +50.0% | 98,797 | +69.8% | 0.01% | +7.7% |
| Q2 2020 | $3,553,000 | -46.1% | 58,200 | -59.4% | 0.01% | -65.8% |
| Q1 2020 | $6,589,000 | -51.3% | 143,359 | -6.9% | 0.04% | -45.7% |
| Q4 2019 | $13,517,000 | +147.4% | 154,038 | +158.9% | 0.07% | +105.9% |
| Q3 2019 | $5,463,000 | +85.9% | 59,500 | +157.5% | 0.03% | +78.9% |
| Q2 2019 | $2,938,000 | +7.3% | 23,105 | +32.7% | 0.02% | +18.8% |
| Q1 2019 | $2,739,000 | +61.1% | 17,408 | +1.6% | 0.02% | +45.5% |
| Q4 2018 | $1,700,000 | -57.0% | 17,137 | -36.8% | 0.01% | -38.9% |
| Q3 2018 | $3,957,000 | – | 27,100 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 4,282,827 | $13,019,794 | 1.84% |
| Birchview Capital, LP | 455,200 | $1,383,808 | 1.18% |
| PFM Health Sciences, LP | 6,040,934 | $18,364,439 | 0.86% |
| Lion Point Capital, LP | 531,256 | $1,615,018 | 0.72% |
| Endurant Capital Management LP | 251,785 | $765,426 | 0.69% |
| Bleichroeder LP | 900,000 | $2,736,000 | 0.67% |
| Connacht Asset Management LP | 31,634 | $96,167 | 0.57% |
| Granahan Investment Management | 5,137,778 | $15,618,845 | 0.56% |
| Frazier Life Sciences Management, L.P. | 1,709,907 | $5,198,117 | 0.34% |
| Contrarius Investment Management Ltd | 1,308,002 | $3,976 | 0.22% |